Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26113746 | 0.79 | PARP1 (0.49) | PARP1EPHX2L3MBTL1DDB1CRBN | |
| SCHEMBL7248991 | 0.76 | PARP1 (0.47) | PARP1EPHX2L3MBTL1DDB1CRBN | |
| SCHEMBL1488276 | 0.74 | L3MBTL1 (0.56) | EPHX2L3MBTL1DDB1CRBNKMT2A | |
| SCHEMBL11052192 | 0.74 | KMT2A (0.59) | L3MBTL1DDB1CRBNKMT2AMEN1 | |
| SCHEMBL1466305 | 0.73 | KMT2A (0.60) | PARP1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL29630944 | 0.73 | KMT2A (0.60) | PARP1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL9766509 | 0.73 | CASP3 (0.46) | PARP1EPHX2L3MBTL1DDB1CRBN | |
| SCHEMBL26112971 | 0.71 | DRD3 (0.44) | PARP1EPHX2L3MBTL1DDB1CRBN | |
| SCHEMBL26114530 | 0.71 | DRD3 (0.44) | PARP1EPHX2L3MBTL1DDB1CRBN | |
| SCHEMBL26112976 | 0.71 | DRD3 (0.44) | PARP1EPHX2L3MBTL1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220101-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2022-07-14 | — | — | US | disclosed |
| US-11339146-B2 | Compositions and methods for viral sensitization | Ottawa Hospital Research Institute and University of Ottawa (CA) | 2022-05-24 | — | — | US | disclosed |
| US-20200354351-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2020-11-12 | — | — | US | disclosed |
| US-20180112190-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2018-04-26 | — | — | US | disclosed |
| US-6924377-B2 | Process for preparing highly functionalized γ-butyrolactams and γ-amino acids | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1499583-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | Warner-Lambert Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20030236415-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | BLAZECKA PETER G (CA) | 2003-12-25 | — | — | US | disclosed |
| US-20030225149-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | BLAZECKA PETER G (CA) | 2003-12-04 | — | — | US | disclosed |
| WO-2003093220-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236415-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | GABRB2, GABRG2, GABRB1 | PARP1 2734/4885EPHX2 2014/4885L3MBTL1 4593/4885 |
| US-11339146-B2 | Compositions and methods for viral sensitization | CD4, CD74, HLA-DRB1 | PARP1 4670/4885EPHX2 2037/4885L3MBTL1 1820/4885 |
| US-20220220101-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | PARP1 4367/4885EPHX2 2855/4885L3MBTL1 1084/4885 |
| US-20030225149-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | GABRB2, GABRG2, GABRB1 | PARP1 2734/4885EPHX2 2014/4885L3MBTL1 4593/4885 |
| US-20200354351-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | PARP1 4367/4885EPHX2 2855/4885L3MBTL1 1084/4885 |
| US-20180112190-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | PARP1 4367/4885EPHX2 2855/4885L3MBTL1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.